Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated substantial weight reduction and cardiometabolic benefit in randomized trials; however, prospective implementation evidence from digital care models and female sex community populations remains limited.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Donna Ryan
Beyond the Scale: Assessing the Quality of Weight Loss and Advancing a Whole-Person Approach to Obesity Care
Beyond the Scale: Assessing the Quality of Weight Loss and Advancing a Whole-Person Approach to Obesity Care What changes when weight changes? Join us for breakfast and explore strategies to assess weight-loss quality, preserve muscle health, and address residual cardiovascular risk in obesity care.
Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04476-6, published online 5 June 2026. In the version of the article initially published, in Fig. 3b, the Aleniglipron 120 mg column initially listed LS mean change as “–12.1” and has been updated to read “–12.7,” while in Fig. 4, the data was missing from the bottom-right panel, and all arrows were missing from the “Vomiting” panels. Figures 3 and 4 have now been corrected in the HTML and PDF versions of the article.
American Diabetes Association Scientific Sessions
Key takeaways: CagriSema was tied to HbA1c and weight reductions in three different populations of adults with type 2 diabetes. Researchers said the drug could provide additive benefits beyond glycemic control and weight loss. NEW ORLEANS —A once-weekly combination therapy of cagrilintide and semaglutide reduced HbA1c and body weight across a wide range of adults with type 2 diabetes, according to data from three phase 3 trials.
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial
Abstract Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in development for obesity treatment. The ACCESS phase 2b placebo-controlled, double-blind study randomized 230 adults (mean BMI 39.5 kg m−2, 54% female) with obesity or overweight to examine the effects of once-daily aleniglipron escalated every 4 weeks to 45, 90 or 120 mg.
Sugar Plum Thumbprint Cookies Original
Home Dishes & Beverages Cookies Thumbprint Cookies Sugar Plum Thumbprint Cookies Recipe photo by Taste of Home TEST KITCHEN APPROVED Sugar Plum Thumbprint Cookies Recipe photo by Taste of Home TEST KITCHEN APPROVED Total Time:Prep: 40 min. Bake: 15 min./batch Taste of Home's Editorial Process Updated on Jun. 05, 2026 Jump to Recipe Save Saved Saving Getting your Trinity Audio player ready...
Amylin analog induces up to 10.7% weight loss at 42 weeks with ‘favorable’ safety profile
Key takeaways: Petrelintide is a once-weekly amylin analog currently under investigation for the treatment of obesity. The tolerability profile of petrelintide was similar to placebo over a 42-week period. A once-weekly amylin analog conferred up to 10.7% weight loss at 42 weeks among adults with overweight or obesity and featured a safety profile similar to placebo, according to topline results from the ZUPREME-1 trial.
Amylin analog induces up to 10.7% weight loss at 42 weeks with ‘favorable’ safety profile
Key takeaways: Petrelintide is a once-weekly amylin analog currently under investigation for the treatment of obesity. The tolerability profile of petrelintide was similar to placebo over a 42-week period. A once-weekly amylin analog conferred up to 10.7% weight loss at 42 weeks among adults with overweight or obesity and featured a safety profile similar to placebo, according to topline results from the ZUPREME-1 trial.
In-Pulse CPR Special Report: How Dangerous is Highway Driving to Heart Health?
via AB Newswire By Donna Ryan, In-Pulse CPR The Hidden Cardiovascular Threat: Why Heavy Traffic is a Heart Hazard The stress of the daily commute, particularly when snarled in heavy traffic, is often dismissed as a routine nuisance. However, mounting scientific evidence indicates that prolonged exposure to congested driving conditions is not merely an inconvenience; it poses a significant, measurable, and potentially lethal risk to cardiovascular health.
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
Get full text access Log in, subscribe or purchase for full access. References 2. Blüher, M Obesity: global epidemiology and pathogenesis Nat Rev Endocrinol. 2019; 15:288-298 3. Garvey, WT ∙ Mechanick, JI ∙ Brett, EM ∙ et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity Endocr Pract. 2016; 22:1-203 4. Garvey, WT ∙ Umpierrez, GE ∙ Dunn, JP ∙ et al.
ESC HF 25: PRAISE-HFrEF: Glucagon-Like Peptide-1 Receptor Agonism in HFrEF and Obesity
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.
Glucagon‐like peptide‐1 receptor agonists lower risk of cardiovascular and non‐cardiovascular mortality: A meta‐analysis of eleven cardiovascular outcome trials
CONFLICT OF INTEREST STATEMENT Y.M.K has nothing to disclose. E.A.B. reports research grant support through Brigham and Women's Hospital from: Abbott; Amgen; Anthos Therapeutics, Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi-Sankyo; Ionis; Merck; Novartis; Pfizer; Saghmos Therapeutics; Verve Therapeutics; and consulting fees from Novo Nordisk, CeleCor Therapeutics, Kowa Pharmaceuticals, and the Scleroderma Research Foundation.
Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study
What is already known? The Epitomee capsule is a novel, oral, self-administered medical device for weight management, consisting of superabsorbent, pharmaceutical-grade polymers and bonding materials that self-expand in the stomach to form a triangular gel scaffold. In a prospective, single-arm, 12-week study in participants with overweight or obesity, the Epitomee capsule significantly reduced body weight, improved cardiometabolic risk factors and satiety, and had a favorable safety profile.
SELECT ‘legitimized obesity medical therapy’ for treatment of cardiometabolic disease
You've successfully added Obesity in Endocrinology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: SELECT cemented weight pharmacotherapy as a path for CV risk reduction.
"Long-Term Weight Loss Effects of Semaglutide in Obesity Without Diabet" by Donna H Ryan, Ildiko Lingvay et al.
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years.
ECO 24: Semaglutide in Body Weight & Reversion of Normoglycaemia: STEP 10
Video Published: Views: 34 Likes: 0 Average (ratings) ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk). This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes.
ECO 24: Increasing GLP1-RA Efficacy by Targeting Non-coding RNA
Video Published: Views: 31 Likes: 0 Average (ratings) ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA. Questions 1. What is the background of this combinatory approach? 2. What data did you present at ERA 24? 3. What are the challenges and opportunities in approaching combinatory treatment? 4. Where are the knowledge gaps? 5.
Adults with obesity, preexisting CVD maintain weight loss with semaglutide at 4 years
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: Of adults receiving semaglutide, 44.2% lost at least 10% of their body weight at 2 years. Those in the semaglutide group reduced their waist circumference 7.7 cm at 4 years.
Medicare to cover semaglutide for CV prevention for adults with overweight and obesity
Donna H. Ryan, MD The emergence of semaglutide, which was approved by the FDA in 2021 at 1.7 mg and 2.4 mg for chronic weight management as Wegovy, was received with much enthusiasm by patients. The molecule had been approved for use in diabetes management as Ozempic in 2017 and is used at doses of 0.5 mg, 1.0 mg and 2.0 mg.
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
What is already known about this subject? The phase 3 Semaglutide Treatment Effect in People with Obesity (STEP) program demonstrated that, overall, semaglutide 2.4 mg was well tolerated by patients with overweight or obesity, and its safety profile was consistent with the glucagon-like peptide-1 receptor agonist class, with no unexpected findings.
Experts warn against walking on frozen grass to avoid damaging the health of your lawn
Frozen grass on a wintery morning. Many gardeners put in lots of time and effort to get a pristine lawn, and all that effort can potentially be spoiled by not keeping off the grass when it is frozen in winter. Ice and frosts leave grass very susceptible to being damaged. Walking on frozen grass damages the turf in several ways and means it may not grow back properly when the temperatures start to rise again in spring.
VIDEO: Which is the superior method for weight loss - drugs or surgery?
You've successfully added Cardiology: CHD/Prevention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: Among weight-loss therapies, bariatric surgery has the most robust long-term data.
Obesity as a Disease: Changing the Paradigm
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Robert F. Kushner, MD: Hi. I am Dr Robert Kushner. Welcome to Medscape's InDiscussion series on obesity. This is episode two.
When health plans are detrimental to diabetes care
Source/Disclosures Source: Healio Interviews Disclosures: Ryan reports no relevant financial disclosures. Weiner reports serving as a consultant to Insulet. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Prevalence of obesity increasing among US adults with diabetes
Source/Disclosures Disclosures: Ryan reports serving as an adviser for Amgen, Altimmune, Calibrate, Gila, Lilly, Novo Nordisk, Scientific Intake, Wondr Health, Xeno Bioscience, Ysopia and Zealand. Hu reports no relevant financial disclosures. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Trends in obesity prevalence and cardiometabolic risk factor control in US adults with diabetes, 1999-2020
ORIGINAL ARTICLE Gang Hu and Jonathan Ding contributed equally to this work. Funding information: National Institute of General Medical Sciences, Grant/Award Number: U54GM104940; Louisiana Department of Health Abstract Objective Trends in obesity prevalence and trends in control of cardiometabolic risk factors among National Health and Nutrition Examination Survey participants with diabetes from 1999 through 2020 were analyzed.
How much weight does my patient need to lose?
What is the real goal of weight loss? In health care, reducing excess body fat is known to improve many complications faced by patients with obesity. Even modest to moderate weight loss contributes to improvements in health. Normalizing body weight is not required. While our culture promotes an ideal body size, in the health care setting, our attention must focus on achieving health improvement. We need to be more tolerant of variations in body size if patients are healthy.
How Much Weight Does My Patient Need to Lose?
What is the real goal of weight loss? In healthcare, reducing excess body fat is known to improve many complications faced by patients with obesity. Even modest to moderate weight loss contributes to improvements in health. Normalizing body weight is not required. While our culture promotes an ideal body size, in the healthcare setting, our attention must focus on achieving health improvement. We need to be more tolerant of variations in body size if patients are healthy.
New Advances in Obesity Management, but Challenges Remain
This transcript has been edited for clarity. My career has really been around clinical research in obesity and diabetes. I was part of the Diabetes Prevention Program, the Look AHEAD study, and the POUNDS LOST study. I helped develop the DASH diet. All of these studies focused on trying to help patients lose weight so that we can better treat these chronic diseases that are filling our offices.
Why Is Long-term Weight Loss So Difficult?
It's an all-too-common story. A patient loses weight after changing his or her diet and physical activity. Comprehensive lifestyle intervention (behavior changes around diet and physical activity) is foundational to weight loss efforts, including perhaps the addition of drugs, devices, or surgery. These interventions have been shown to produce weight loss associated with many health benefits, and medical cost savings.
Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss
What is already known? ► Most available pharmacotherapies for obesity treatment target appetite regulation. ► Beyond appetite regulation, energy expenditure and fat oxidation are important determinants of weight gain and weight-loss maintenance. ► Most of the drugs stimulating energy expenditure have failed in clinical development because of safety issues or lack of efficacy.
Adherence, not diet type, strong predictor for weight-loss success
December 04, 2021 3 min read Save Source/Disclosures Published by: Source: Ryan D. What’s the best weight loss diet. Presented at: World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease; Dec. 2-4, 2021; Los Angeles (hybrid meeting).
Semaglutide for obesity: four STEPs forward, but more to come
1 Kushner RF Calanna S Davies M et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the step trials 1 to 5. Obesity (Silver Spring). 2020; 28: 1050-1061 and four have been published. Semaglutide 2·4 mg once weekly, an anti-obesity medication now submitted to regulators across the USA and Europe, is generating much excitement and attention about the amount of weight loss it produced in the phase 3 studies.
Setmelanotide: what does it mean for clinical care of patients with obesity?
In The Lancet Diabetes & Endocrinology, Karine Clément, Erica van den Akker, and colleagues present the results of setmelanotide in participants with three of the ultrarare genetic conditions associated with severe childhood obesity. 1 Clément K van den Akker E Argente J et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Evidence‐based weight loss interventions: Individualized treatment options to maximize patient outcomes
Abstract Against the backdrop of obesity as a major public health problem, we examined three questions: How much weight loss is needed to benefit patients with obesity? How well do current therapies do in producing weight loss? What strategies can be used to improve patient outcomes using evidence‐based studies. This paper reviews literature on the outcomes of lifestyle, diet, medications and surgical treatments for obesity using literature searches for obesity treatments.
Energy Balance and Weight Loss for Diabetes Remission
User Name * Password * Sign In to Email Alerts with your Email Address Email * Thank you for your interest in spreading the word about Diabetes Spectrum. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
I WILL mindset make you strong and great
I recently was invited to a party which I was fearful to attend because I did not think I knew a lot of the other guests, so when the host who happens to be a special friend asked if I would be coming, my response was, I'll try my best to be there. It has become very clear to me that I have hidden behind that little apostrophe mark for too long. It is such a safe word, as it makes me sound like a nice person, but it keeps me from having to commit.
Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates.
BACKGROUND The possible advantage for weight loss of a diet that emphasizes protein, fat, or carbohydrates has not been established, and there are few studies that extend beyond 1 year. METHODS We randomly assigned 811 overweight adults to one of four diets; the targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%.
We need to change the narrative around obesity. Here's why
Obesity has become a significant public health issue and with good reason. Over the past 40 years, the number of people living with obesity has almost tripled. Today, more than 650 million adults worldwide have obesity – that’s double the total population of the United States. Furthermore, more than 120 million children and adolescents are living with obesity and a further 210 million are overweight, putting them at risk of having obesity in adulthood.
We need to change the way we think about obesity
The facts are simple: obesity is a crisis for the world. Obesity has become a significant public health issue and with good reason. Over the past 40 years, the number of people living with obesity has almost tripled. Today, more than 650 million adults worldwide have obesity - that’s double the total population of the United States.
Erratum. George A. Bray, MD: Progress in Obesity—Multidisciplinary Research, Multidimensional Man. Diabetes Care 2016;39:1481–1485
In the second paragraph of the print version of the article listed above, it was stated that George Bray worked at G.D. Searle, located in New York, NY. The location was Skokie, IL, a suburb of Chicago.In the sixth paragraph of the article, the authors believe they may have given Dr. Bray’s bench research and his collaborations with David York, PhD less attention than they deserved.
Return on Investment: Medical Savings of an Employer‐Sponsored Digital Intensive Lifestyle Intervention for Weight Loss
Abstract Objective This study aimed to determine the medical cost impact and return on investment (ROI) of a large, commercial, digital, weight-management intensive lifestyle intervention (ILI) program (Real Appeal). Methods Participants in this program were compared with a control group matched by age, sex, geographic region, health risk, baseline medical costs, and chronic conditions.
Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
EVIDENCE OF HEALTH BENEFITS OF DIFFERENT DEGREES OF WEIGHT LOSS 1. Modest and moderate weight loss and diabetes prevention The health benefit of modest weight loss is best exemplified clinically in the relationship between weight loss and diabetes prevention.
George A. Bray, MD: Progress in Obesity-Multidisciplinary Research, Multidimensional Man
George as a child.
Management of obesity
1. WHO obesity and overweight fact sheet no 311. 2. Overweight and obesity. 3. Health and Social Care Information Centre Statistics on obesity, physical activity and diet: England 2015. 4. WHO regional office for Europe Data and statistics. 5. Ng M Fleming T Robinson M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384: 766-781 6.
Dietary Fat Intake Modifies the Effect of a Common Variant in the
Background: Hepatic lipase (HL) plays a pivotal role in the metabolism of HDL and LDL. Recent genome-wide association studies have identified common variants in the HL gene (LIPC) associated with HDL cholesterol. Objective: We tested the effect of a common variant in LIPC on changes in blood lipids in response to weight-loss diets in the Preventing Overweight Using Novel Dietary Strategies Trial.
Predicting successful long-term weight loss from short-term weight-loss outcomes: new insights from a dynamic energy balance model (the POUNDS Lost study)
Background: Currently, early weight-loss predictions of long-term weight-loss success rely on fixed percent-weight-loss thresholds. Objective: The objective was to develop thresholds during the first 3 mo of intervention that include the influence of age, sex, baseline weight, percent weight loss, and deviations from expected weight to predict whether a participant is likely to lose 5% or more body weight by year 1.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Donna
Contact Donna, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack